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Abstract 
BACKGROUND: Breast cancer remains the most common malignancy among the Iraqi population. Affected 
patients exhibit different clinical behaviours according to the molecular subtypes of the tumour. 
AIM: To identify the clinical and pathological presentations of the Iraqi breast cancer subtypes identified by 
Estrogen receptors (ER), Progesterone receptors (PR) and HER2 expressions. 
PATIENTS AND METHODS: The present study comprised 486 Iraqi female patients diagnosed with breast 
cancer. ER, PR and HER2 contents of the primary tumours were assessed through immunohistochemical 
staining; classifying the patients into five different groups: Triple Negative (ER/PR negative/HER2 negative), Triple 
Positive (ER/PR positive/HER2 positive), Luminal A (ER/PR positive/HER2 negative), HER2 enriched ((ER/PR 
negative/HER2 positive) and all other subtypes. 
RESULTS: The major registered subtype was the Luminal A which was encountered in 230 patients (47.3%), 
followed by the Triple Negative (14.6%), Triple Positive (13.6%) and HER2 Enriched (11.5%). Patients exhibiting 
the Triple Negative subtype were significantly younger than the rest of the groups and presented with larger size 
tumours. A significant difference in the distribution of the breast cancer stages was displayed (p < 0.05); the most 
advanced were noted among those with HER2 enriched tumours who exhibited the highest frequency of poorly 
differentiated carcinomas and lymph node involvement. 
CONCLUSION: The most significant variations in the clinicopathological presentations were observed in the age 
and clinical stage of the patients at diagnosis. Adoption of breast cancer molecular subtype classification in 
countries with limited resources could serve as a valuable prognostic marker in the management of aggressive 
forms of the disease. 
 
 
 
 
Introduction 
 
The burden of breast cancer, as the most 
prevalent malignant neoplasm among females 
globally [1] and in Iraq specifically [2], has been 
illustrated comprehensively in numerous surveys that 
emphasised the importance of its early detection and 
control [3], [4], [5], [6], [7], [8]. Evidence suggests that 
patients diagnosed with the disease exhibit different 
clinical behaviour according to the various 
pathological and biological characteristics of the 
tumour; thus, recommending different therapeutic 
strategies. 
Earlier analytic studies on gene expressions 
revealed that the response of the mammary 
carcinoma cell to treatment is determined by intrinsic 
molecular characteristics that could be probed. The 
pioneer molecular portrait presented by Sorlie et al., 
classified breast cancer into five intrinsic subtypes 
with distinct clinical outcomes, i.e., luminal A, luminal 
B, HER2 over-expression, basal and normal-like 
tumours [9], [10]. Later on, immunohistochemical 
(IHC) assays categorised breast cancer into three 
major adopted phenotypes; the Luminal, HER2 
enriched and Triple Negative (TN). 
TN breast cancer is considered a 
heterogeneous group that comprises the basal 
subtypes which are reported to be more frequent 
among younger age patients and exhibit more 
aggressive nature with limited therapeutic options and 
high risk of recurrence [11], [12], [13]. On the other 
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hand, the luminal-like tumours, that express hormone 
receptor, are the most common subtypes that carry a 
good prognosis. They usually respond well to 
hormonal treatment but poorly to conventional 
chemotherapy. While Luminal A could be adequately 
controlled with endocrine treatment, luminal B (triple 
positive TP) phenotypes often tend to be more 
proliferative, yielding relatively higher grade and 
recurrent tumours; thus, recommending combined 
chemotherapy and hormonal treatment [10], [14]. 
Whereas few previous studies registered the 
various breast cancer IHC subtypes among Iraqi 
patients [5], [6], [15], [16], [17], [18], reported data on 
their different behaviours and outcomes to remain 
scanty.  
This study aims at providing further 
information on the clinical and pathological 
presentations of TN Iraqi breast cancer patients as 
compared to the other variants focusing on the triple 
positive (TP) and HER2 enriched phenotypes. 
 
 
Material and Methods 
 
The present study comprised 486 Iraqi female 
patients with a histopathologically confirmed diagnosis 
of mammary carcinoma registered between 2015 and 
2017 at the Oncology Teaching Hospital and the 
National Cancer Research Center, Baghdad, Iraq. 
The studied clinical and pathological parameters were 
obtained from the case sheet records and pathology 
reports of the corresponding patients and included the 
age at diagnosis, tumour type, grade and size, lymph 
node status and the stage of the disease at 
presentation. Written consents were obtained from all 
the patients enrolled in the present work to use the 
relevant recorded information and approval of the 
study design was given by the Ethical Committee of 
the National Cancer Research Center of Baghdad 
University following the ethical standards laid down by 
the Declaration of Helsinki. 
The reported data were reassessed to 
document the requested variables. Pathologically, 
breast cancers were typed according to the WHO 
classification [19] and graded following the modified 
Nottingham Bloom-Richardson categorisation [20]. 
The UICC TNM System was adopted to classify the 
clinical stage of the disease at presentation [21]. 
Evaluation of the Estrogen receptor (ER), 
Progesterone receptor (PR) and HER2 contents of the 
primary tumours was performed through IHC staining 
of the formalin-fixed paraffin-embedded tissue blocks 
using Dako kits (Denmark) including the specific 
monoclonal antibodies [14], [15]. 
The major registered receptor-defined 
subtypes were: - Luminal A (ER/PR positive/HER2 
negative); - Luminal B/Triple Positive (ER/PR 
positive/HER2 positive); - HER2 Enriched (ER/PR 
negative/HER2 positive); and - Triple Negative 
(ER/PR negative/HER2 negative). 
Other recorded subtypes included: - ER 
(positive)/PR (negative)/HER2 (positive); - ER 
(negative)/PR (positive)/HER2 (positive); - ER 
(positive)/PR (negative)/HER2 (negative); and - ER 
(negative)/PR (positive)/HER2 (negative). 
Accordingly, patients were classified into five 
groups: TN (Group I); TP (Group II); Luminal A (Group 
III); HER2 enriched (Group IV); and all other subtypes 
(Group V). 
Statistical correlation to compare the 
demonstrated clinical and pathological features of the 
different breast cancer subtypes was carried out using 
SPSS version 16.0 statistical program. Categorical 
data were presented by frequencies and percentages. 
Chi-square test was used to assess the association 
between the different variables. P values, less or 
equivalent to 0.05, were considered significant. 
 
 
Results 
 
IHC examination of the diagnosed breast 
cancer tissue specimens belonging to 486 patients 
revealed that the total rates of ER, PR and HER2 
positive tumour contents were equivalent to 68.5%, 
66.2% and 29.6% respectively. The major registered 
subtype was the Luminal A (E+/P+/H-) which was 
encountered in 230 patients (47.3%), followed by 
Triple Negative (E-/P-/H-) in 71 patients (14.6%), 
Luminal B/Triple Positive (E+/P+/H+) in 66 patients 
(13.6%) and HER2 Enriched (E-/P-/H+) in 56 patients 
(11.5%). Other encountered phenotypes were rare 
and included in order of frequency: (E+/P-/H-) in 22 
cases (4.5%); (E-/P+/H-) in 19 cases (3.9%); (E+/P-
/H+) in 15 cases (3.1%) and (E-/P+/H+) in seven 
cases (1.4%) (Figure 1, Table 1). 
 
Figure 1: Frequency distribution of Iraqi breast cancer IHC subtypes 
 Table 2 illustrates the clinical and pathological 
presentations of the TN breast cancer subtype 
compared to the TP/Luminal B, HER2 enriched and 
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Luminal A phenotypes. Significant differences were 
noted among the different studied groups concerning 
the age of the patients at presentation (p < 0.05). 
Patients exhibiting the TN subtype were significantly 
younger than the rest of the groups (69% under the 
age of 50 years versus 52% overall). 
Table 1: Overall rates of the reported breast cancer subtypes 
among Iraqi patients 
 IHC Subtype ER* 
Status 
PR** 
Status 
HER2*** 
Status 
IHC 
Phenotypes 
Total 
No. 
Total 
 
% 
1 Luminal 
B/Triple 
Positive 
E+ P+ H+ E+/P+/H+ 66 13.6 
2 Triple Negative E- P- H- E-/P-/H- 71 14.6 
3 Luminal A E+ P+ H- E+/P+/H- 230 47.3 
4 HER-2 
Enriched 
E- P- H+ E-/P-/H+ 56 11.5 
5 E+/P-/H+ E+ P- H+ E+/P-/H+ 15 3.1 
6 E-/P+/H+ E- P+ H+ E-/P+/H+ 7 1.4 
7 E+/P-/H- E+ P- H- E+/P-/H- 22 4.5 
8 E-/P+/H- E- P+ H- E-/P+/H- 19 3.9 
Total      486 100 
*Total Estrogen Receptor rate: 68.5%; **Total Progesterone Receptor rate: 66.2%; ***Total 
HER2 rate: 29.6%. 
 
Although the rate of Lobular carcinoma was 
higher among group III (Luminal A), yet the 
differences in frequencies of the various histologic 
types of breast cancer were not statistically significant.  
Table 2: Clinical and tumour characteristics categorized 
according to the examined breast cancer subtypes 
 
 
Group I E-/P-
/H-TN* 
Group II 
E+/P+/H+TP**  
Luminal B 
Group III 
E+/P+/H- 
Luminal A 
Group VI E-/P-
/H+Her2- 
Enriched 
Group V All 
other 
Subtypes 
Overall 
Total 
Subtypes 
 
p-value 
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)  
Age (years) 
<   50 
=>50 
 
49 
22 
 
69.0 
31.0 
 
33 
33 
 
50 
50 
 
107 
123 
 
46.5 
53.5 
 
28 
28 
 
50 
50 
 
36 
27 
 
57.1 
42.9 
 
253 (52.1) 
233 (47.9) 
11.863. 
P=0.0184 
Significant 
Tumour Type 
Ductal 
Lobular  
In situ 
Others/mixed 
Unknown 
 
56 
5 
0 
4 
6 
 
78.9 
7 
0 
5.6 
8.4 
 
53 
4 
2 
2 
5 
 
80.3 
6.1 
3.0 
3.0 
7.6 
 
171 
21 
11 
13 
14 
 
74.4 
9.1 
4.7 
5.7 
6.1 
 
48 
1 
1 
2 
4 
 
85.7 
1.8 
1.8 
3.6 
7.1 
 
49 
3 
1 
4 
6 
 
77.8 
4.8 
1.6 
6.3 
9.5 
 
377  (77.6) 
33     (6.8) 
11     (2.3) 
18     (3.7) 
47     (9.7) 
 
7.259 
p=0.848 
NS 
Tumour Grade 
I  
II  
III 
Unknown 
 
2 
50 
13 
6 
 
2.8 
70.4 
18.3 
8.4 
 
0 
41 
12 
13 
 
0 
62.1 
18.1 
19.7 
 
14 
153 
32 
31 
 
6 
66.5 
13.9 
13.5 
 
0 
35 
15 
6 
 
0 
62.5 
26.8 
10.7 
 
0 
39 
14 
10 
 
0 
61.9 
22.2 
15.9 
 
16      (3.3) 
318  (65.4) 
86    (17.7) 
66    (13.6) 
 
13.0145 
p=0.016 
NS 
Tumour Size 
T1 
T2 
T3 
T4 
Tx 
 
11 
34 
18 
4 
4 
 
15.5 
47.9 
25.3 
5.6 
5.6 
 
10 
43 
9 
2 
2 
 
15.1 
65.2 
13.6 
3 
3 
 
48 
128 
31 
10 
13 
 
20.9. 
7 
13.5 
4.3 
5.6 
 
6 
35 
8 
2 
5 
 
10.7 
62.5 
14.2 
3.6 
8.9 
 
13 
39 
5 
2 
4 
 
20.6 
61.9 
7.9 
3.2 
6.3 
 
88    (18.1) 
279  (57.4) 
71    (14.6) 
20     (4.1) 
28     (5.8) 
 
16.321 
P=0.4308 
NS 
LN Status 
N0 
N+  
Nx 
 
20 
42 
9 
 
28.1 
59.1 
12.7 
 
20 
40 
6 
 
30.3 
60.6 
9 
 
79 
135 
16 
 
34.3 
58.7 
7 
 
14 
38 
4 
 
25 
67.9 
7.1 
 
20 
39 
4 
 
31.7 
61.9 
6.3 
 
153  (31.5) 
294  (60.5) 
39     (8.0) 
 
2.045 
p=0.563 
NS 
Stage 
I & II 
III & IV Unknown 
 
37 
27 
7 
 
57.8 
42.2 
 
37 
24 
5 
 
60.7 
39.3 
 
133 
82 
15 
 
61.9 
38.1 
 
20 
32 
4 
 
38.5 
61.5 
 
35 
24 
4 
 
59.3 
40.7 
 
262 (53.90 
189  (38.9) 
35     (7.2) 
 
9.6886. 
P=0.0460 
Significant 
Total 71       (14.6) 66       (13.6) 230     (47.3) 56         (11.5) 63     (13.0) 486   (100)  
*Triple Negative; **Triple Positive 
 
Likewise, whereas the highest frequency of 
poorly differentiated mammary carcinomas was 
observed among group IV (HER2) subtype (26.8% 
versus 17.7% overall), such difference was not 
significant. Larger size tumours (T3 and T4) were 
more common in patients with the group I (TN) 
phenotype (30.9% versus 16.6%, 17.8%, 17.8% and 
11.1% in groups II, III, and IV and V respectively). 
More than two-thirds of patients in group IV (HER2) 
presented with metastatic lymph node involvement 
(67.9%); that rate was higher than the other subtypes. 
Nevertheless, Chi-square statistics failed to reveal any 
significant variations between the studied groups 
regarding tumour size or nodal status. On the other 
hand, a statistical difference in the distribution of 
breast cancer stages was displayed (p < 0.05); with 
significantly more advanced stages (III and IV) noted 
in patients with HER2 enriched subtypes (61.5%) 
compared to 42.2%, 39.3% and 38.1% in groups I, II 
and III respectively. 
 
 
Discussion 
 
Cancer is currently forming a major public 
health concern in Iraq; being responsible for the 
second cause of death among the general population 
[2], [22], [23]. Iraqi studies, in particular, have 
displayed the emerging dilemma of controlling breast 
cancer, the most common registered malignancy, 
which is increasingly diagnosed alarmingly among 
middle-aged females at quite advanced stages [4], [5], 
[6], [7], [8], [23]. It has been well established that racial 
disparities contribute to the various morphologies and 
presentations of breast cancer among patients in 
different ethnic groups reflecting the reported 
discrepancy in incidence, prognosis and survival from 
the disease [24], [25], [26], [27]. The molecular 
diversity of breast cancer illustrated in genomic 
analytic studies promoted the development of targeted 
therapies to the genetic alterations that drive certain 
identified cancer subtypes. The registered frequencies 
of ER+, PR+ and HER2+ breast cancers in the 
present work were 68.5%, 66.2% and 29.6% 
respectively. Whereas the corresponding figures from 
western studies are significantly higher for ER+ and 
PR+ breast cancers, they are statistically lower for 
HER2+ tumours contributing to better outcomes of the 
disease in well-developed regions of the world [5], 
[24], [25], [26], [27], [28], [29]. 
As observed in earlier studies from Iraq [5], 
[15], [16], [17], [18] and the literature [9], [10], [11], 
[12], [13], [14], [24], [25], [26], [27], [28], [29], [30], 
[31], [32], [33] the major registered breast cancer 
subtype was Luminal A (47.3%) that comprises 
positive hormone receptors in the absence of HER2 
overexpression; stimulating the favorable biological 
behavior of the disease in the affected patients. While 
the displayed rate is close [29] and almost higher than 
those documented in surveys from Arab countries 
[30], [31], yet it is significantly lower than those 
reported in Western studies [5], [24], [25], [26], [27], 
[28]. Focusing on molecular characteristics and 
management implications of breast cancer in Arab 
populations, it was noted that disparities in these 
regions were not only confined to the 
clinicopathological features but existed as well at the 
molecular levels as reflected in the relevant genomic 
expression profiles [5], [27], [29], [30], [31]. A recent 
study on the comparative behaviour of breast cancer 
among Iraqi and British patients pointed out to 
heterogeneity of the underlying tumour biology that 
reflected genetic susceptibility. The authors concluded 
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that the significantly younger ages and advanced 
stages at the presentation of breast cancer among 
Iraqi patients, associated with the higher rates of TN 
and HER2 enriched phenotypes, recommended 
comprehensive assessment of the surrogate subtypes 
to ensure effective approaches in the management of 
the disease in Iraq [5]. Such higher rates of 
aggressive breast cancer subtypes among patients 
from low-middle income countries compared to those 
living in high-income societies were illustrated in 
earlier surveys [27], [29], [30], [31], [32], [33]. The 
second prevalent breast cancer subtype observed in 
the present work (14.6%) was the TN which is 
characterised by the negative expressions of ER, PR 
and HER2. 
Interestingly that frequency was close to the 
rate recorded in the Annual Report to the Nations on 
the incidence of breast cancer subtypes in the US 
[28]; highlighting the significantly low prevalence of 
hormone receptor-negative tumours among the 
American patients. Consistent with the findings 
displayed earlier by other investigators, patients 
bearing this subtype in our study were significantly 
younger than those exhibiting the other phenotypes 
and presented with larger size tumours at the time of 
diagnosis [11], [12], [13]. However, they were less 
likely to have poorly differentiated tumours and 
positive lymph node involvement than group IV; the 
HER2-enriched tumour counterparts. Whereas 
previous reports showed that TN breast cancer 
tumours with more positive axillary lymph node, higher 
clinical stages and histological grades leading to 
aggressive clinical behaviour [34], [35], others 
demonstrated that TN encompasses a wide spectrum 
of entities possessing different biological and clinical 
attitudes including low-grade disease with indolent 
behaviour and favourable outcome [36], [37].  
In general, patients exhibiting the HER2 
enriched variant, which constituted 11.5% of total 
subtypes in the present work, displayed the highest 
frequency of poorly differentiated cancers and 
metastatic lymph nodes. It has been recorded in the 
literature that between 15-25% of breast cancers 
possess overexpression of HER2 and yield 
unfavourable clinical outcome [28], [38], [39]. The 
registered rates of HER2 + subtypes in the Arab 
series are quite higher [29], [40]; pointing out to the 
elevated prevalence of less differentiated tumours in 
the region [29], [30], [31], [40], [41]. Such regional and 
ethnic differences in the grades of the tumour are 
most probably related to genetic, biological and 
environmental factors. TP Luminal B subtype formed 
about 13.6% in the present study; close to the findings 
reported in previous studies from Iraq [5], [6], [15], 
[16], [18], and the neighboring countries [41], [42]. In a 
recent survey performed on a cohort of Iraqi patients 
presenting with breast cancer, no significant 
differences were noted in the clinicopathological 
presentations of patients with this phenotype 
compared to the others apart from the variation in the 
distribution of tumour types; where infiltrative ductal 
carcinomas were more common [16]. That was in 
contrast to the findings observed in another study 
which showed that invasive ductal carcinomas were 
preponderant among the TN subtypes [36]. Similar to 
other studies [43], the data of this work did not reveal 
any statistical differences in the distribution of the 
histological types among the examined groups, 
though the rate of lobular carcinoma was more 
common among patients with Luminal A.  
Concerning the breast cancer stage at 
presentation, our results revealed a significant 
difference in the distribution among the various groups 
(p < 0.05); with the highest frequency of advanced 
stages (III and IV) being observed among those 
harbouring the HER2 enriched subtypes. It has been 
displayed in the literature that hormone-receptor-
positive breast cancer expressions are often 
associated with earlier stages at presentation and that 
HER2+ impact is reflected by poorly differentiated 
tumours and advanced stages [39].  
A recently published Iraqi study correlating 
the stage of breast cancer at the time of diagnosis 
with the clinicopathological characteristics of the 
affected patients demonstrated that 64.4% and 67.2% 
exhibiting Luminal A and Luminal B subtypes 
respectively were diagnosed at Stages I and II 
whereas 68% and 62% of those harbouring the TN 
and HER2+ respectively presented at advanced 
stages (III and IV) [6]. Comparative retrospective 
evaluation of the clinical features and survival 
outcomes of 1134 invasive breast cancer subtypes 
showed that the overall five-year survival was almost 
similar in TN and HER2 subtypes, nevertheless, 
subjects with HER2 presented at later stages with 
more frequent local recurrences [44]. 
In conclusion, patients within the TN group 
were statistically younger and exhibited larger tumour 
sizes than others. On the other hand, poorly 
differentiated tumours and metastatic lymph node 
involvement were more commonly encountered 
among patients with HER2 subtype who presented 
with significantly more advanced stages at the time of 
diagnosis. Adopting molecular subtype classification 
of breast cancer, as a cost-effective, reliable clinical 
investigation in countries with limited resources, is 
recommended to provide a feasible tool for assessing 
the response to therapy and to serve as a valuable 
prognostic marker in the management of aggressive 
forms of the disease among younger patients. 
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